Samsung Epis Holdings Co Ltd
0126Z0
Company Profile
Business description
Samsung Epis Holdings Co Ltd focuses on the development and commercialization of biopharmaceuticals. The company is engaged in development and commercialization of biosimilars, concentrating on various disease areas including autoimmune diseases, oncology, ophthalmic diseases, hematological diseases, and bone diseases.
Contact
76 Songdogyuk-ro
Yeonsu-gu
Incheon
KORT: +82 327280114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
Ongoing rate hikes have investors spooked.
stocks
ASX dividend champions: Stocks, ETFs and LICs
Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks
SpaceX’s IPO filing: Big spending, big losses
The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.80 | 9.50 | -0.11% |
| CAC 40 | 8,086.00 | 31.42 | -0.39% |
| DAX 40 | 24,606.77 | 130.47 | -0.53% |
| Dow JONES (US) | 49,908.14 | 101.21 | -0.20% |
| FTSE 100 | 10,443.47 | 11.13 | 0.11% |
| HKSE | 25,386.52 | 264.60 | -1.03% |
| NASDAQ | 26,152.51 | 117.85 | -0.45% |
| Nikkei 225 | 61,684.14 | 1,879.73 | 3.14% |
| NZX 50 Index | 12,878.07 | 117.04 | 0.92% |
| S&P 500 | 7,407.43 | 25.54 | -0.34% |
| S&P/ASX 200 | 8,621.70 | 6.30 | -0.07% |
| SSE Composite Index | 4,077.28 | 84.91 | -2.04% |